C0920321||Phase I
C2603343||Study
C1254351||Pilaralisib
C3657458||SAR245408
C2347424||XL147
C0281297||Combination with Paclitaxel and Carboplatin
C0280100||Solid Tumors
C0007621||tumorigenesis
C0280100||solid tumors
C4041090||PI3K inhibitors
C1516654||clinical activity
C4041090||PI3K pathway inhibitors
C3665472||chemotherapy
C0243095||antitumor effects
C0280100||solid tumors
C4041090||PI3K inhibitor
C1254351||pilaralisib
C1705187||safety
C1979963||profile
C0243095||antitumor activity
C0281297||paclitaxel plus carboplatin
C4084924||clinical evaluation
C0013162||combination
C4041090||PI3K pathway inhibitors
C1254351||Pilaralisib
C3657458||SAR245408
C1272919||oral
C0441885||pan-class I
C4041090||phosphoinositide 3-kinase (PI3K) inhibitor
C0920321||phase I
C2603343||study
C0220825||evaluated
C1705187||safety
C0031327||pharmacokinetics
C0031327||pharmacokinetics
C0851347||pharmacodynamics
C1254351||pilaralisib
C0006935||capsule
C0039225||tablet
C0013058||formulations
C0281297||combination with paclitaxel and carboplatin
C0280100||solid tumors
C1254351||Pilaralisib
C0144576||paclitaxel
C0079083||carboplatin
C0599755||cohort
C0476089||endometrial carcinoma
C0013221||toxicities
C0015230||rash
C1254351||pilaralisib
C0039225||tablets
C0281297||combination with paclitaxel and carboplatin
C0700287||reported
C0877248||adverse events
C0877248||adverse events
C0441800||grade
C0027947||neutropenia
C0040034||thrombocytopenia
C0031327||pharmacokinetics
C1513916||no
C0687133||interaction
C1254351||pilaralisib
C0281297||paclitaxel/carboplatin
C0475358||Tumor tissue
C0021469||inhibition
C1518102||mitogen-activated protein kinase (MAPK) pathways
C1521726||partial response
C1521726||partial response
C1254351||Pilaralisib
C1705187||safety
C1979963||profile
C0243095||antitumor activity
C0281297||paclitaxel plus carboplatin
C0280100||solid tumors